Sarepta Therapeutics announced research agreement with U.S. DoD to evaluate multiple constructs from proprietary RNA platform as treatments for COVID-19
| | | |

Sarepta Therapeutics announced research agreement with U.S. DoD to evaluate multiple constructs from proprietary RNA platform as treatments for COVID-19

On Apr. 28, 2020, Sarepta Therapeutics announced the Company and the USAMRIID, the Department of Defense’s lead laboratory…

Yield10 Bioscience obtains positive response from USDA-APHIS on regulatory status of CRISPR genome-edited C3007 trait in camelina, paving way for US Field Tests
| | | |

Yield10 Bioscience obtains positive response from USDA-APHIS on regulatory status of CRISPR genome-edited C3007 trait in camelina, paving way for US Field Tests

On Apr. 27, 2020, Yield10 Bioscience announced it has obtained a positive response from USDA-APHISï¾’s Biotechnology Regulatory Services…

Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
| | |

Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…